Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
Skin Therapy Lett
; 26(1): 1-4, 2021 Jan.
Article
em En
| MEDLINE
| ID: mdl-33539061
ABSTRACT
Atopic dermatitis (AD) is a chronic, relapsing, inflammatory condition marked by pruritus and traditionally treated with topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI). Crisaborole 2% ointment (a topical phosphodiesterase-4 inhibitor) is a newer topical agent for the treatment of AD. Crisaborole is indicated for treating mild-to-moderate AD and evidence from phase 3 and phase 4 trials show that crisaborole is an effective agent with a well-tolerated side effect profile for children >2 years of age. The most common side effects are pain and paresthesia at the application site. Treatments with tolerable safety profiles such as crisaborole may provide an alternative to patients with TCS phobia. The role of crisaborole in AD therapy may become clearer as multiple phase 4 trials are currently underway and their results are poised to answer more questions, including its safety profile for patients as young as 3 months of age, potential use as a steroid-sparing agent, and direct comparisons to TCS and TCI, which are the current mainstay treatments of mild-to-moderate AD.
Palavras-chave
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Compostos de Boro
/
Compostos Bicíclicos Heterocíclicos com Pontes
/
Dermatite Atópica
/
Fármacos Dermatológicos
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article